Ionis Pharmaceuticals Aktienanalyse: Milliardenmarkt im Blick - RBC Capital erkennt den nächsten Wachstumsschub

Bad Marienberg (www.aktiencheck.de)???????? Ionis Pharmaceuticals hebt ab: RBC Capital sieht neues Kursziel 95 USD und enormes MarktpotenzialIonis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) steht nach der jüngsten Aktienanalyse von RBC Capital im Rampenlicht der Biotech-Branche. [mehr]

Ionis - Biotechkonzern überzeugt mit starker Pipeline!

Der Biotechkonzern hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen spezialisiert. Mit Spiranza (spinale Muskelatrophie (SMA)), Tegsedi (hereditären...

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JPMorgan upgrades biopharma stock to overweight on strong drug pipeline

JPMorgan foresees shares of Ionis Pharmaceuticals rising another 16% from their Tuesday close after a 170% runup in six months.

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript

Ionis Pharmaceuticals Aktie: Positive Phase-3-Daten beflügeln Analystenmeinung - Upgrade!

New York (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Goldman Sachs:Salveen Richter von Goldman Sachs stuft die Aktie von Ionis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) von "sell" auf "neutral" hoch.Das Unternehmen erkläre, dass sich Ionis zu einer kommerziellen Wachstumsgeschichte entwickelt und seine Antisense-Oligonukleotid-Technologie optimiert habe. [mehr]

Ionis Pharmaceuticals: BofA-Analyst erhöht Kursziel und rät zum Kauf nach Phase-3-Erfolg

Bad Marienberg (www.aktiencheck.de) - ???? Ionis Pharmaceuticals: BofA Securities setzt neue AkzenteIonis Pharmaceuticals sorgt erneut für Schlagzeilen: BofA Securities hat am 23. September 2025 sein Kursziel für die Aktie leicht, aber bedeutend von 81 USD auf 83 USD angehoben. Das Rating bleibt weiterhin auf "buy". [mehr]

Ionis Pharmaceuticals Aktie: Phase-3-Erfolg bei Alexander-Krankheit beflügelt Kursziel

London (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Barclays:Die Analystin Gena Wang von Barclays bestätigt für die Aktie von Ionis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) ein Rating "overweight" und hebt das Kursziel von 78 auf 82 USD an. [mehr]

Ionis Pharmaceuticals Aktienanalyse: Tryngolza und Dawnzera starten durch - Raymond James passt Kursziel an!

Bad Marienberg (www.aktiencheck.de)???? Ionis Pharmaceuticals begeistert Analysten: Raymond James hebt Kursziel auf 75 USD - "strong buy"Ionis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) steht wieder einmal im Rampenlicht der Wall Street - und das mit voller Wucht. [mehr]

Ionis Pharmaceuticals - Biotechkonzern überrascht mit positiven Studiendaten zu Olezarsen

Geschäftstreiber: Der US-Biotech-Konzern Ionis Pharmaceuticals (IONS) hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen spezialisiert. Mit Spiranza...

Ionis Pharmaceuticals: Blockbuster-Potenzial als Kurstreiber

Ionis Pharmaceuticals ist ein führender Entwickler von Medikamenten, die auf der Antisense-Technologie basieren. Diese Technologie zielt darauf ab, die Produktion schädlicher Proteine zu stoppen,...

Ionis (IONS) Q2 Revenue Soars 101%

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins.The profit surge in Q2 2025 included a non-recurring $280 million licensing payment. Sustainable profitability remains tied to future commercial and regulatory milestones.These 10 stocks could mint the next wave of millionaires › Ionis Pharmaceuticals (NASDAQ:IONS), a biotechnology company focused on RNA-targeted therapeutics, reported its...

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

· Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA · European Commission decision expected by Q4 2025 Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the ...

Ionis Pharmaceuticals - US-Biotechkonzern überzeugt mit starker Pipeline!

Geschäftstreiber: Der US-Biotech-Konzern Ionis Pharmaceuticals (IONS) hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen spezialisiert. Mit Spiranza...

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of May 28, 2025. The video was published on Jul. 2, 2025.Should you invest $1,000 in Kiniksa Pharmaceuticals International right now? Before you buy stock in Kiniksa Pharmaceuticals International, consider this:Where to i...

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Heres What You Should Know

The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Big Pipeline Updates From Kiniksa Pharmaceuticals

Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus By Investing.com

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus

Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.